<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089219</url>
  </required_header>
  <id_info>
    <org_study_id>10464</org_study_id>
    <secondary_id>UVACC-MEL-41</secondary_id>
    <secondary_id>UVACC-28502</secondary_id>
    <nct_id>NCT00089219</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma</brief_title>
  <official_title>Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

      PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and
      comparing them to see how well they work in treating patients with stage IIIB, stage IIIC, or
      stage IV melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the immune response in patients with stage IIIB, IIIC, or IV melanoma treated
           with vaccine comprising multiple synthetic melanoma peptides, Montanide ISA-51, and
           sargramostim (GM-CSF).

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 3 treatment arms.

        -  Arm I: Patients receive vaccine comprising low-dose multiple synthetic melanoma
           peptides, Montanide ISA-51, and sargramostim (GM-CSF) on days 1, 8, 15, 29, 36, and 43.

        -  Arm II: Patients receive vaccine comprising medium-dose multiple synthetic melanoma
           peptides, Montanide ISA-51, and GM-CSF as in arm I.

        -  Arm III: Patients receive vaccine comprising high-dose multiple synthetic melanoma
           peptides, Montanide ISA-51, and GM-CSF as in arm I.

      On day 22, the lymph node draining the vaccination site is removed to determine whether the
      immune system is responding to the vaccine.

      PROJECTED ACCRUAL: A maximum of 38 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Dose-limiting toxicity</measure>
    <time_frame>During study period</time_frame>
    <description>Toxicities measured by CTCAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>day 22</time_frame>
    <description>Melanoma peptide-specific helper T cell responses in the sentinel immunized node (SIN) on day 22.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response in the blood</measure>
    <time_frame>day 50</time_frame>
    <description>Immune response measured in the blood, by proliferation assay, over time during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTH response</measure>
    <time_frame>by day 85</time_frame>
    <description>Delayed-type hypersensitivity response to tumor peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>during the study</time_frame>
    <description>Clinical tumor response</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm A. 6MHP vaccine 200 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B. 6MHP vaccine 400 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C. 6MHP vaccine 800 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFA</intervention_name>
    <description>vaccine adjuvant</description>
    <arm_group_label>Arm A. 6MHP vaccine 200 mcg</arm_group_label>
    <arm_group_label>Arm B. 6MHP vaccine 400 mcg</arm_group_label>
    <arm_group_label>Arm C. 6MHP vaccine 800 mcg</arm_group_label>
    <other_name>incomplete Freund's adjuvant, Montanide ISA-51</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>6MHP</intervention_name>
    <description>melanoma helper peptides</description>
    <arm_group_label>Arm A. 6MHP vaccine 200 mcg</arm_group_label>
    <arm_group_label>Arm B. 6MHP vaccine 400 mcg</arm_group_label>
    <arm_group_label>Arm C. 6MHP vaccine 800 mcg</arm_group_label>
    <other_name>multi-epitope melanoma peptide vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>vaccine adjuvant</description>
    <arm_group_label>Arm A. 6MHP vaccine 200 mcg</arm_group_label>
    <arm_group_label>Arm B. 6MHP vaccine 400 mcg</arm_group_label>
    <arm_group_label>Arm C. 6MHP vaccine 800 mcg</arm_group_label>
    <other_name>sargramostim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of stage IIIB, IIIC, or IV melanoma

          -  HLA-DR1, -DR4, -DR11, -DR13, or -DR15 positive

          -  Brain metastases allowed at the discretion of the principle investigator

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count &gt; 1,000/mm^3

          -  Platelet count &gt; 100,000/mm ^3

          -  Hemoglobin &gt; 9 g/dL

        Hepatic

          -  Liver function tests ≤ 2.5 times upper limit of normal (ULN)

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No New York Heart Association class III or IV heart disease

        Other

          -  Prior diagnosis of other cancer allowed

          -  Not pregnant or nursing

          -  Weight ≥ 110 pounds

          -  No uncontrolled diabetes

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 4 weeks since prior growth factors

          -  More than 4 weeks since prior allergy shots

          -  More than 12 weeks since prior melanoma vaccine therapy* NOTE: *Prior melanoma vaccine
             allowed only for patients with disease progression during or after administration of
             the vaccine

          -  No prior vaccination with any of the peptides used in this study

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy

        Endocrine therapy

          -  More than 4 weeks since prior steroids

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

        Surgery

          -  Not specified

        Other

          -  More than 1 month since prior investigational drugs or therapies

          -  No other concurrent investigational drugs or therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008 Oct 20;26(30):4973-80. doi: 10.1200/JCO.2008.17.3161. Epub 2008 Sep 22.</citation>
    <PMID>18809608</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

